|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS
From Rockefeller University, New York, NY; Okayama
Prefectural University, Okayama, Japan; Cornell University-Northshore
Hospital, Long Island, NY; Phillips University, Marburg,
Germany; Universite Catholique de Louvain, Bruxelles, Belgium;
University Hospital of Antwerp, Belgium; and Huddinge University
Hospital, Huddinge, Sweden.
The properties of 9 Delta-aminolevulinate dehydratase (ALAD) deficiency
porphyria (ADP) is an autosomal recessive disorder caused by a
homozygous ALAD deficiency. Patients with this condition have clinical
symptoms of acute hepatic porphyria such as abdominal pain, vomiting,
pain in the arms and legs, and neuropathy. ALAD is the second enzyme in
the heme biosynthetic pathway. It catalyzes the Knorr-type condensation
of 2 molecules of aminolevulinate acid (ALA) to form a monopyrrole,
porphobilinogen (PBG).1 This enzyme activity is present in
large excess compared to other enzymes in the heme biosynthetic
pathway, and its partial deficiency does not usually result in any
clinical consequences. Seven patients with ADP have been reported to
date,2-6 though only 4 of them have been confirmed by
immunochemical or molecular analysis.2-4 Of these 4 cases, the first 2 were German patients reported by Doss and
coworkers,7 the third was a Swedish baby boy studied by
Thunell and colleagues,8 and the fourth was an elderly
Belgian man reported by Hassoun and associates.9 Recently,
an asymptomatic Swedish baby girl has been identified to have a
markedly decreased ALAD activity.10 Thus far, a total of 9 point mutations of the alad gene have been identified in
these 5 subjects, which resulted in different amino acid changes.
However, the enzymatic activity of ALAD expressed by mutant ALAD was
investigated only for 4 mutants, A274T and R240W, in German patient
B,3 and V153M and delTC in German patient H11
(single-letter amino acid codes). This previous study with German
patient B demonstrated that ALAD activity contributed by the R240W
allele was less than 10% of that of the wild type, whereas the A274T
allele produced an unstable protein.3 Thus the compound
heterozygosity of an inactive protein and an unstable protein accounted
for an almost complete lack of ALAD activity (< 2% of normal) in the
proband. German patient H had also compound heterozygous mutations,
V153M with a decreased ALAD activity,12 whereas delTC
was a frame-shift mutation resulting in no ALAD protein.13
The first Swedish child with ADP studied by Plewinska and
coworkers4 was also compound heterozygous for ALAD
deficiency (G133R and V275M).
Although homozygous or compound heterozygous deficiency of ALAD is
extremely rare, enzyme activities below 50% of normal are not
exceptional in the population, as found in 16 of 880 individuals examined in a Swedish study.8 If these individuals are
heterozygous carriers of ALAD deficiency, the prevalence of this
condition is about 2% in a normal population. Clinical implications of
these findings are obvious in that these individuals with low ALAD
activity may be more vulnerable than normal subjects to toxic effects
of chemicals or compounds such as lead,14,15
trichloroethylene,16 styrene oxide,17 or
bromobenzene,18 which inhibit ALAD
activity.19 It is thus important to identify heterozygous
carriers of ALAD deficiency and to define the nature of their enzymatic defect.
With this view in mind, we examined the enzymologic and immunochemical
properties of 9 mutant ALADs so far identified in patients with ADP. We
used pGEX plasmid, which can be used for inducible, intracellular
expression of genes as fusion proteins with the Schistosoma
japonicum glutathione S-transferase (GST)
gene encoding a 26-kd protein. Fusion proteins can be purified in a
single step directly from bacterial lysates by using
glutathione-affinity chromatography.20 The fusion proteins
have also been successfully used in enzyme assays without removing
GST.21-24 In this study, we purified 9 different ALAD
mutants as GST-fusion proteins that had been expressed in pGEX-3X
plasmid, and used them to characterize their phenotype.
Characterization of the mutant proteins was performed by enzymatic
assays of ALAD activity, immunoblot analysis of ALAD-GST protein using
both polyclonal and monoclonal antibodies (MAbs) against antihuman
ALAD, and examination of thermostability.
Case reports
German patient 1.7
This is one of the first 2 patients with ADP reported by Doss and
coworkers.7 The patient was referred to as patient B in
the original report.7 The patient developed sudden
abdominal cramps, with nausea, constipation, and vomiting when he was
15 years old. Because of the "strong abdominal pain," he underwent an appendectomy. A distal motor polyneuropathy, hypertonus of the
muscle, tachycardia, and loss of appetite also developed with paralysis
of extensors, during acute phases. Urinary ALA excretion, but not PBG,
was markedly elevated (Table 1).
Erythrocyte ALAD activities of the patient, the father, the mother, one
brother, and a sister were less than 1%, 43%, 25%, 38%, and 46% of
normal, respectively (Table 1). Thus, these subjects can be considered heterozygous for ALAD deficiency, whereas the patient was homozygous for the enzymatic defect. Another brother had an enzymatic activity within the normal range, representing a normal family member (Table 1).
Similar ALAD deficiency was also confirmed in lymphocytes isolated from
these subjects.25 Molecular analysis of the
alad gene defect demonstrated that the patient was compound
heterozygous for A274 and R240W mutations.3
German patient 2.7
This patient was referred to as patient H in the original
report.7 The patient, a 15-year-old boy, also suddenly
developed vomiting, pains in arms and legs with sensory disturbances,
followed by loss of appetite. He was admitted to a neurologic clinic
because of paralysis, which included respiratory muscles. Urinary ALA and porphyrin excretion was elevated (Table 1). Molecular analysis of
the alad gene defect demonstrated that the patient was
compound heterozygous for V153M and delTC
mutations.12,13
Belgian patient.9 The patient was a 63-year-old man. At the age of 63, he developed a gradually worsening loss of strength in both arms.28 The patient showed markedly elevated plasma ALA concentration (110 µg/dL; normal < 10); plasma PBG was undetectable. Urinary ALA excretion (85 mg/dL; normal < 5) was also abnormally elevated, without an increase in PBG concentration. Erythrocyte ALAD activity of the patient was less than 1% of normal controls,9 whereas lymphocyte ALAD activity was about 20% of normal controls25 (Table 1). Other causes of ALAD deficiency, such as lead poisoning, tyrosinemia, alcoholism, smoking, cirrhosis, renal insufficiency, and diabetes mellitus were excluded.9 Both oral glucose and intravenous infusion of glucose were effective in ameliorating biochemical and clinical abnormalities related to porphyria. Family studies showed that, except for a brother who had normal levels of enzyme activity, a sister, a daughter, and a granddaughter of the patient had about 50% ALAD activity compared with normal controls,28 indicating that these subjects are heterozygous carriers of ALAD deficiency. Molecular analysis revealed that the patient was heterozygous for G133R and K59N mutations in one ALAD allele.29 Swedish symptomatic child (Swedish 1).8 In contrast to the 3 previous patients, severe symptoms were already present in this patient at birth. This is highly unusual for patients with acute hepatic porphyria, who commonly develop clinical disease at puberty or after.30 At the age of 3, he had recurrent attacks of pain, vomiting, and hyponatremia and symptoms of polyneuropathy involving motor functions including respiratory muscles. The patient excreted large amounts of ALA and coproporphyrin in the urine, but only moderately elevated levels of PBG (~5-fold of the normal upper limit; Table 1). Erythrocyte protoporphyrin was also moderately increased (6-fold of the normal control). Erythrocyte ALAD activity was less than 5% of normal in the patient, and between 26% and 51% in both parents, both grandfathers, and a sibling. Attempts to treat the porphyria syndrome of the patient by glucose, hematin, or blood were unsuccessful.4 At the age of 6, the patient underwent liver transplantation.31 Although the postoperative period was complicated by episodes of severe paralysis and respiratory failure requiring respirator support, the patient's condition gradually improved, and the patient was free from pain.4 He needed assisted ventilation intermittently, but his condition permitted him to attend school at times. Two years and 9 months after the transplantation, at the age of 9 years, the boy died. The immediate cause of death was pneumonia, respiratory insufficiency, and finally pneumothorax. At autopsy his diaphragm and intercostal muscles looked unusually thin. Histopathologic investigation showed demyelinization of peripheral nerves and neurogenous muscular atrophy within several muscle groups. The transplanted liver was macroscopically and microscopically normal (S. Thunell, L. Holmberg, and J. Lundgren, personal oral communications, July 1998). Molecular analysis of the alad gene defect indicated that the patient was compound heterozygous for G133R and V153M mutations.4 Swedish asymptomatic girl (Swedish 2).10 This asymptomatic newborn child had a marked reduction in erythrocyte ALAD activity (~12% of normal). The child is in good health and has normal growth and normal neuromuscular and intellectual development. There are signs of deranged heme biosynthesis because urinary ALA and coproporphyrin are slightly increased, as is erythrocyte protoporphyrin concentration. Urinary PBG is normal. Hereditary tyrosinemia and lead poisoning have been excluded by specific assays. Molecular analysis of the alad gene defect demonstrated that the child is heterozygous for F12L mutation.11 Plasmid construction Mutant ALAD complementary DNAs (cDNAs) (K59N, G133R, K59N/G133R, F12L, V153M, delTC), which have been identified in patients with ADP,12,13,32 were cloned by reverse transcription-polymerase chain reaction (RT-PCR). Mutant R240W, A274T, and V275M ALAD cDNA were prepared using QuickChange site-directed mutagenesis kit (Stratagene, La Jolla, CA) using the wild-type human ALAD cDNA as a template according to the manufacturer's protocol. Three sets of oligomers harboring the point mutation of interest (indicated by a bold letter) were used as a mutagenic primer: For R240W: 5'-CCGAGCTGTGGACTGGGATGTACGGG-3' (sense), and 5'-CCCGTACATCCCAGTCCACAGCTCGG-3' (antisense), and A274T: 5'-CCCTGACCTCCCTCTCACCGTGTACCACG-3' (sense), and 5'-CGTGGTACACGGTGAGAGGGAGGTCAGGG-3' (antisense), and V275M: 5'-CCTCCCTCTCGCCATGTACCACGTCTCTGG-3' (sense), and 5'-CCAGAGACGTGGTACATGGCGAGAGGGAGG -3' (antisense). These mutant cDNAs were inserted into pGEM-T Easy, or pGEM-T plasmids (Promega, Madison, WI), and were reconstructed into BamHI site-attached plasmids as follows. The wild-type ALAD and F12L mutant ALAD containing BamHI site at the 5' end were synthesized by PCR, using each ALAD cDNA as a template. An oligomer, 5'-GGATCCATATGCAGCCCCAGTCCGTTCT-3', was synthesized and used as a sense primer, whereas an oligomer, 5'-GGAAACAGCTATGACCATG-3' (M13 reverse, Promega) was used as an antisense primer. The reaction mixture (100 µL) contained 100 pmol of each primer, 0.25 µg human ALAD cDNA as a template, 2.5 U Taq DNA polymerase (Roche, Nutley, NJ), dNTPs (200 µmol each), and 10 µL 10 × PCR buffer (Roche). PCR was carried out using a Thermal Cycler (Perkin Elmer Cetus, Norwalk, CT). The samples were denatured at 94°C for 2 minutes, followed by 15 cycles of amplification that included heating at 94°C for 1 minute, 60°C for 1 minute, and 72°C for 90 seconds. PCR products were purified using QIAEX II Agarose Gel Extraction System (Qiagen, Chatsworth, Canada), and were inserted into pGEM-T Easy vector. K59N, G133R, K59N/G133R, V153M, R240W, A274T, and delTC mutant cDNA plasmids were digested with restriction enzymes, and DNA fragments harboring these mutation(s) or deletion were inserted into a BamHI site-attached wild-type ALAD plasmid, by digestion with the identical restriction enzyme(s). After confirmation of both wild-type and mutant ALAD sequences by nucleotide sequencing, the plasmids were digested with BamHI and EcoRI, then cDNA fragments were ligated to pGEX-3X plasmids (Pharmacia, Uppsala, Sweden). Their sequences were again confirmed by sequencing, or by restriction analysis (data not shown).Expression and purification of the wild-type and mutant ALAD as GST-fusion proteins The GST-fusion proteins were expressed and purified by a minor modification of the method as previously described.20,33 The pGEX-3X plasmids coding the wild-type and mutant alad genes were transformed into Escherichia coli BL21 (DE3)PlysS (Novagen, Madison, WI). Transformed cells were grown in 400 mL Luria-Bertani (LB) medium containing 50 µg/mL ampicillin and 170 µg/mL chloramphenicol at 37°C for 3 hours. Then, isopropyl-1-thio- -D-galactoside (IPTG, Sigma Chemical,
St Louis, MO) was added to a final concentration of 0.05 mM to induce
fusion protein expression. Induced cells were grown at 25°C for an
additional 7 hours and centrifuged at 4°C. The collected cells were
resuspended in 16 mL buffer A, which consisted of 50 mM HEPES (pH 7.5),
1 mM EDTA, and 5 mM dithiothreitol (DTT) containing 0.1% Triton X-100,
10 µg/mL antipain (Sigma), 10 µg/mL leupeptin (Sigma), and 10 µg/mL pepstatin A (Sigma). Then, the samples were frozen at  80°C
overnight. After thawing the samples on ice, DNase, Rnase, and
MgCl2 were added to a final concentration of 50 µg/mL,
100 µg/mL, and 5 mM, and centrifuged. The supernatant fractions were
applied to glutathione Sepharose 4B affinity column (Pharmacia), and
then washed 3 times with washing buffer (50 mM Hepes [pH 7.5], 1 mM
ZnSO4, and 5 mM DTT, 10 µg/mL antipain, 10 µg/mL
leupeptin, and 10 µg/mL pepstatin A). The fusion proteins were eluted
with an elution buffer (50 mM Hepes [pH 7.5], 1 mM ZnSO4,
5 mM DTT, and 10 mM glutathione, adjusted to pH 7.5) and stored at
80°C until used.
Antibodies against human ALAD A rabbit antihuman ALAD polyclonal antibody had been prepared by immunizing 3 rabbits with a homogeneously purified ALAD preparation from normal human erythrocytes, and had been purified to its IgG, as described previously,34 and used as a polyclonal antibody. MAbs against human ALAD were prepared using male BALB/c mice. The spleen cells were fused to mouse myeloma cells after 2 or 3 injections of purified human ALAD34 to animals. Hybridomas were cloned and selected by enzyme-linked immunosorbent assay (ELISA) using purified human ALAD. As a result, 3 MAbs, that is, MAb4, MAb330, and MAb350, were selected for positive binding to the wild-type ALAD.Immunoblot analysis of fusion proteins The purified fusion proteins were heated at 100°C for 3 minutes in sodium dodecyl sulfate (SDS) gel-loading buffer (50 mM Tris-Cl [pH 6.8], 100 mM DTT, 2% SDS, 0.1% bromophenol blue, and 10% glycerol). The samples were loaded on to a 10% polyacrylamide gel containing 0.01% SDS (SDS-PAGE), and electrophoresed according to the method described previously.35 Samples were then transferred to a sheet of nitrocellulose membrane and incubated overnight at 4°C with 5% skim milk in Tris-buffered saline-0.1% Tween 20. The membrane was incubated with the primary antibody for 1 hour at room temperature. Goat antimouse IgG (Santa Cruz Biotech, Santa Cruz, CA), or goat antirabbit IgG (Santa Cruz Biotech), conjugated with horseradish peroxidase was used as a secondary antibody. Protein bands to which antibodies were bound were visualized with the enhanced chemoluminescence (ECL) immunoblotting system (Amersham International, Buckinghamshire, United Kingdom), which was performed according to manufacturer's protocol.ALAD activity assay The ALAD activity of purified GST-fusion proteins was determined colorimetrically as described previously, and expressed as units per milligram protein.1 Protein concentration was determined by using the Biorad Protein Assay System (Biorad, Hercules, CA). ALAD activity was expressed as the percent of that of the wild-type ALAD.
Expression and purification of fusion proteins The wild-type and mutant ALADs were ligated to pGEX-3X plasmid and transformed into E coli BL21 (DE3)PlysS. These ALADs were expressed as GST-fusion proteins and were purified using glutathione-affinity column chromatography. Fusion protein synthesis in E coli was induced by IPTG, and then soluble proteins were collected. The estimated molecular size of all GST-fusion ALADs is 62 kd, except for that of delTC which is 58 kd, based on the assumption of the sizes of 26 kd, 36 kd,36 and 32 kd, for GST, ALAD, and mutant delTC, respectively. The size for the mutant delTC was estimated on the basis of the total length of the coding region of its cDNA. A single major protein band corresponding to a monomer of GST-ALAD fusion protein was observed for the purified fusion protein preparation by staining with Coomassie brilliant blue R (Figure 1). This finding suggests that the GST-ALAD fusion protein has been highly purified by glutathione-affinity chromatography.
Immunoblot analysis All GST-ALAD fusion proteins, including the wild-type and mutant ALADs, were detected as a single band at the predicted size by immunoblot analysis using mouse MAb against GST (Figure 2A). The protein expressed by delTC was smaller than by other ALAD cDNAs by about 4 kd, as expected by its premature stop codon (Figure 2A). When rabbit antihuman ALAD antibody was used, there was a major band at the same size that was detected by anti-GST MAb for all fusion proteins, but there was additionally a minor band with a higher molecular size (~64 kd), for most samples (Figure 2B). The extra band detected by a polyclonal antibody to human ALAD was at the same size for all samples, but not detectable by any MAbs against human ALAD, suggesting that the extra band was derived from E coli.
The MAbs against human ALAD were prepared as IgG using male BALB/c mice. The spleen cells were fused with mouse myeloma cells after 2 or 3 times injection of purified human ALAD to animals. Hybridomas were cloned and evaluated by ELISA for their binding to purified human ALAD. As a result, 3 MAbs, that is, MAb4, MAb330, and MAb350, were selected for positive binding to the wild-type ALAD. The MAbs against human ALAD were diluted to a 1000-fold in buffered saline for Western blotting. Both MAb4 and MAb350 detected the same size protein as did anti-GST MAb (Figure 2C,D), but there was no extra band detected by the polyclonal antibody (Figure 2B). MAb330 did detect the same protein for all samples, except for delTC (Figure 2E). Although the wild-type and mutants except delTC were recognized by the 3 MAbs, delTC failed to cross-react with MAb330. The delTC mutation, namely, 818T819C deletion,13 encoded completely abnormal amino acids after 272P, and resulted in a new stop codon at 293I, as opposed to the wild-type ALAD, which consists of 330 amino acids. Accordingly, the molecular size of delTC ALAD should be 32 kd, instead of 36 kd. Thus, the C-terminal sequence of delTC ALAD should be completely different from that of the wild-type ALAD. These findings suggest that, although MAb4 and MAb350 recognize epitopes encoded by amino acid sequences N-terminal to 272P, MAb330 recognizes an epitope encoded by sequences C-terminal to this site. ALAD activity of fusion proteins The ALAD activity of mutant ALADs was determined using GST-ALAD fusion proteins.1 The activity of each mutant ALAD was expressed as the ratio to that of the wild-type ALAD (Figure 3). The wild-type ALAD is fully active as a GST-fusion protein. Among mutant-GST fusion proteins, K59N showed the highest activity, that is, 69.9% of the wild type, followed by V153M and A274T, which showed 41.0% and 19.3% activity of the wild type, respectively. In contrast, the activity of other mutants were all under 10% of the wild type, specifically, 8.1%, 8.1%, 0.5%, 3.5%, and 1.2%, for G133R, K59N/G133R, F12L, R240W, V275M, and delTC, respectively. These results demonstrate that mutants G133R, F12L, R240W, V275M, and delTC had little enzymatic activity, whereas mutants K59N, A274T, and V153M had a partial but significant ALAD activity, as a GST-ALAD fusion protein. It is also clear that the activity of K59N/G133R was determined by the low activity of G133R in the same allele.
To examine thermostability of ALAD mutants, ALAD activity of GST-fusion proteins that had a significant enzyme activity were determined after preincubation for 15 minutes at 37°C, 40°C, 50°C, 60°C, or 70°C. Enzyme activity was expressed as the ratio to that which was measured at 37°C without preincubation. The wild-type enzyme, K59N, A274T, and V153M proteins showed no decline in ALAD activity up to 50°C, whereas the activity was reduced to about 60% to 75% by preincubation at 60°C or 70°C. These findings indicate that K59N, A274T, and V153M proteins had similar thermostability to that of the wild-type ALAD.
In this study, we have prepared 9 mutant ALAD cDNAs so far identified in patients with ADP, 6 mutants by site-directed mutagenesis, and 3 mutants by subcloning from patients' lymphoid cells, expressed them as a GST-fusion protein in E coli, and purified the fusion protein by glutathione-affinity column chromatography. We then studied immunochemical and enzymologic properties of the purified proteins by using a polyclonal antibody and MAbs raised against the normal human ALAD, and by examining enzyme activity and thermostability. ALAD-GST fusion proteins were detectable by immunoblot analysis by using rabbit IgG and mouse MAbs against human ALAD, and a mouse MAb against E coli GST. It is of special interest to note that ALAD activity of the expressed proteins was measurable as a GST-fusion protein. In comparison to ALAD activity expressed by the wild-type ALAD cDNA, enzyme activities of mutants were 69.9%, 8.1%, 8.1%, 0.5%, 3.5%, 19.3%, 7.1%, 41.0%, and 1.2% for K59N, G133R, K59N/G133R, F12L, R240W, A274T, V275M, V153M, and delTC, respectively. Results with A274T and R240W ALAD were consistent with our previous findings on the expression of these proteins in Chinese hamster ovary (CHO) cells3; that is, mutant R240W ALAD showed little enzymatic activity, whereas mutant A274T ALAD showed partial activity. Results with V153M and delTC, which had been identified in German patient B, also confirmed our findings on the phenotype of these proteins expressed in CHO cells.11 The effect of heat treatment for 15 minutes prior to enzyme assay
revealed that 3 mutants with significant ALAD activity had similar
thermostability. These findings suggest that these mutant proteins have
no overt structural abnormality, despite the fact that they have some
reduced catalytic activity. Human ALAD has a Mr of 280 000 and 36 000
kd for the homooctamer and for the subunit, respectively. It is thought
that mammalian ALAD is active only as the homooctamer, though the
prokaryotic enzyme appears to be active as a monomer.37
According to the x-ray crystallographic analysis of yeast ALAD, the
dominant feature of the monomer is the closed ( Many GST-fusion proteins are known to be immunoreactive as well as enzymologically active.21-23 It is important to note that ALAD deficiency in vivo in patients with ADP is largely consistent with the phenotype of GST-ALAD fusion proteins, suggesting that the bacterial expression of mutant proteins is useful for studies of human mutant ALADs. The advantage of the GST expression system is that the expressed protein can be readily purified by a single-step glutathione-affinity chromatography. Because ALAD is exceptionally sensitive to the toxic effects of certain chemicals such as lead, trichloroethylene, styrene oxide, and succinylacetone, the enzyme holds a unique place in toxicology as the sensitive target of environmental insults.17,19,39-41 It is thus important to examine the enzymologic and toxicologic characteristics of mutant ALAD phenotypes, and purified GST-fusion ALAD offers a useful model for these studies. The structural analysis of the yeast ALAD has permitted insights into
the basis for the malfunction of 5 mutant ALA enzymes.38 For example, the K59N mutation is thought not to prevent the folding or
the functioning of the enzyme. This is consistent with our finding that
demonstrated that K59N mutant had the highest ALAD activity (~70% of
the wild type) among all mutants examined. It is also consistent with
the fact that this mutant is highly abundant in the normal population
(~10% of the population).42,43 In this context, K59N
should more appropriately be termed as a variant, rather than a mutant
of ALAD. Four other mutants identified in ADP, G133R, R240W, A274T, and
V275M, were thought to have significant structural effects on the
enzyme molecule.38 For example, glycine 133, which is
adjacent to the 3 cysteine residues (cysteine 132 in human ALAD,
equivalent to 143 in yeast) that form the zinc binding site at the
active center, can be disrupted by substitution of an arginine for
glycine 133, which may alter the zinc binding and catalytic activity of
the enzyme. Consistent with this prediction, our findings indicate that
ALAD activity expressed by G133R was 8.1% of that of the wild-type
ALAD. F12L, a new mutant ALAD identified in an asymptomatic Swedish
child with heterozygous ALAD deficiency, had ALAD activity less than
1% of the wild type. This mutation occurred in the Amino acids encoded by mutant delTC are completely different from the
wild type at amino acids after 272P due to
T816C817 deletion. The 2-base substitution
occurred at the site next to A274T mutation characterized by us
previously, which was known to accompany little enzyme
activity.3 This mutation also directly influences In contrast, V153M mutation is located in the In the study of German patient H who showed little ALAD activity in erythrocytes, we identified mutants V153M and delTC.11 The activity of mutant V153M ALAD and delTC were, however, 41% and 1.2% of the wild-type ALAD. Why the combination of V153M and delTC resulted in little enzyme activity in vivo in the patient is unclear, but it appears that delTC produces a dominant negative effect on the expression of ALAD in vivo in the patient. The Belgian patient with a late-onset ADP is particularly noteworthy. In this patient, 2 mutations of the alad gene, K59N and G133R, were detected in the same allele; however, the other allele was entirely normal. The protein encoded by G133R alone had little activity (~8% compared with that of the wild type), and the mutant containing both K59N/G133R had a similar activity as G133R alone. This patient was unique in that he developed the disease only at age 63, which was remarkably late.7-9 This patient also developed ADP in conjunction with polycythemia.28 Polycythemia is a clonal disorder and progeny of a single cell can gain ascendancy in the bone marrow, which presumably carried the mutant alad allele, resulting in clinical ADP in the patient.29 The study using antihuman ALAD mouse MAb in immunoblot analysis of ALAD deficiency in ADP has proven extremely useful in characterizing distinct immunologic epitopes of mutant ALAD identified in patients. Namely, although MAb4 and MAb350 recognized all ALAD mutants similarly as did a rabbit polyclonal IgG against human ALAD, both in immunoblot analysis in this study and in ELISA (data not shown), MAb330 failed to recognize protein encoded by delTC in both assays. Based on the mutant amino acid sequences, and the recognition by MAbs, it can be concluded that MAb330 recognizes an epitope that is encoded by amino acid sequences after 272P, whereas MAb4 and MAb350 recognize epitopes encoded by amino acids prior to this residue. These findings indicate the usefulness of a panel of MAbs in the structural analysis of mutant ALAD proteins. The findings in this study also indicate that ALAD mutations identified in ADP are highly heterogeneous, and the mechanisms of developing ADP are also variable.
We are grateful to Dr George Drummond for his reading this manuscript and for his helpful comments.
Submitted October 2, 2000; accepted January 17, 2001.
Supported in part by a General Clinical Research Center grant (M01-RR00102) from the National Center for Research Resources at the National Institutes of Health; U.S. Public Health Service grant DK32890 (to S.S.); Chugai Fund for Molecular Hematology (to S.S.); Yamanouchi Molecular Medicine Fund (to S.S.); the German Research Association grant GR 1363/2-2 (to M.O.D.); and Karolinska Institute Research Grant (to P.H.).
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Shigeru Sassa, Head, Laboratory for Biochemical Hematology, Rockefeller University, New York, NY 10021; e-mail: sassa{at}rockvax.rockefeller.edu.
1.
Sassa S.
2. Sassa S. ALAD porphyria. In: Berk PD, ed. Seminars in Liver Disease. New York, NY: Thieme; 1998:95.
3.
Ishida N, Fujita H, Fukuda Y, et al.
Cloning and expression of the defective genes from a patient with
4.
Plewinska M, Thunell S, Holmberg L, Wetmur JG, Desnick RJ.
5. Wolff C, Piderit F, Armas-Merino R. Deficiency of porphobilinogen synthase associated with acute crisis: diagnosis of the first two cases in Chile by laboratory methods. Eur J Clin Chem Clin Biochem. 1992;29:313. 6. Muraoka A, Suehiro I, Fujii M, Murakami K. delta-aminolevulinic acid dehydratase deficiency porphyria (ADP) with syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in a 69-year-old woman. Kobe J Med Sci. 1995;41:23[Medline] [Order article via Infotrieve]. 7. Doss M, von Tiepermann R, Schneider J, Schmid H. New type of hepatic porphyria with porphobilinogen synthase defect and intermittent acute clinical manifestation. Klin Wochenschr. 1979;57:1123[CrossRef][Medline] [Order article via Infotrieve]. 8. Thunell S, Holmberg L, Lundgren J. Aminolevulinate dehydratase porphyria in infancy: a clinical and biochemical study. J Clin Chem Clin Biochem. 1987;25:5[Medline] [Order article via Infotrieve]. 9. Hassoun A, Verstraeten L, Mercelis R, Martin J-J. Biochemical diagnosis of an hereditary aminolaevulinate dehydratase deficiency in a 63-year-old man. J Clin Chem Clin Biochem. 1989;27:781[Medline] [Order article via Infotrieve]. 10. Harper P, Floderus Y, Holme E, Thunell S. Twelve per cent erythrocyte aminolevulinate dehydratase activity in a healthy child [abstract]. Porphyrins and Porphyrias 1997, Hamburg, Germany.
11.
Akagi R, Yasui Y, Harper P, Sassa S.
A novel mutation of 12. Akagi R, Meguro K, Doss M, Sassa S. Molecular studies of the gene defect of ALA dehydratase deficiency porphyria: a new point mutation identified in a second German patient. Porphyrins 1992;1:267-272.
13.
Shimizu R, Akagi R, Meguro K, Doss M, Sassa S.
Molecular studies of the gene defect of
14.
Granick JL, Sassa S, Granick S, Levere RD, Kappas A.
Studies in lead poisoning, II: correlation between the ratio of activated to inactivated
15.
Doss M, Laubenthal F, Stoeppler M.
Lead poisoning in inherited
16.
Koizumi A, Fujita H, Sadamoto T, Yamamoto M, Kumai M, Ikeda M.
Inhibition of
17.
Fujita H, Koizumi A, Hayashi N, Ikeda M.
Reduced synthesis of
18.
Fujita H, Ishihara N.
Reduction of 19. Sassa S, Fujita H, Kappas A. Genetic and chemical influences on heme biosynthesis. In: Kotyk A,Skoda J,Paces V,Kostka V, eds. Highlights of Modern Biochemistry. Utrecht, The Netherlands: VSP International Science Publishers; 1989:329. 20. Smith DB, Johnson KS. Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase. Gene. 1988;67:31[CrossRef][Medline] [Order article via Infotrieve].
21.
Rivas S, Bolland S, Cabezon E, Goni FM, de la Cruz F.
TrwD, a protein encoded by the IncW plasmid R388, displays an ATP hydrolase activity essential for bacterial conjugation.
J Biol Chem.
1997;272:25583
22.
Yacoub A, Kelley MR, Deutsch WA.
Drosophila ribosomal protein PO contains apurinic/apyrimidinic endonuclease activity.
Nucl Acids Res.
1996;24:4298 23. Kakonen SM, Hellman J, Pettersson K, Lovgren T, Karp M. Purification and characterization of recombinant osteocalcin fusion protein expressed in Escherichia coli. Protein Expr Purif. 1996;8:137[CrossRef][Medline] [Order article via Infotrieve]. 24. Kanno H, Fujii H, Miwa S. Expression and enzymatic characterization of human glucose phosphate isomerase (GPI) variants accounting for GPI deficiency. Blood Cells Mol Dis 1998;24:54[CrossRef][Medline] [Order article via Infotrieve].
25.
Sassa S, Fujita H, Doss M, et al.
Hereditary hepatic porphyria due to homozygous
26.
de Verneuil H, Doss M, Brusco N, Beaumont C, Nordmann Y.
Hereditary hepatic porphyria with
27.
Gross U, Sassa S, Deybach J-C, Nordmann Y, Frank M, Doss MO.
5-Aminolevulinic acid dehydratase (ALAD) deficiency porphyria: a 20 year clinical and biochemical follow up.
Clin Chem.
1998;44:1892-1896
28.
Mercelis R, Hassoun A, Verstraeten L, De Bock R, Martin J-J.
Porphyric neuropathy and hereditary
29.
Akagi R, Nishitani C, Harigae H, et al.
Molecular analysis of 30. Kappas A, Sassa S, Galbraith RA, Nordmann Y. The porphyrias. In: Scriver CR,Beaudet AL,Sly WS,Valle D, eds. The Metabolic and Molecular Basis of Inherited Disease. New York, NY: McGraw-Hill; 1995:2103. 31. Thunell S, Henrichson A, Floderus Y, et al. Liver transplantation in a boy with acute porphyria due to aminolaevulinate dehydratase deficiency. Eur J Clin Chem Clin Biochem. 1992;30:599[Medline] [Order article via Infotrieve]. 32. Horie Y, Meguro K, Fujita H, et al. Molecular analysis of the gene defects of ALA dehydratase deficiency porphyria developed in an elderly patient. Porphyrins. 1993;2:143-148.
33.
Furuyama K, Fujita H, Nagai T, et al.
Pyridoxine refractory X-linked sideroblastic anemia caused by a point mutation of the erythroid-specific 5-aminolevulinate synthase gene.
Blood.
1997;90:822-830
34.
Chang CS, Sassa S, Doyle D.
An immunological study of 35. Haid A, Suissa M. Immunochemical identification of membrane proteins after sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Method Enzymol. 1983;96:192[Medline] [Order article via Infotrieve].
36.
Akagi R, Prchal JT, Eberhart CE, Sassa S.
An acquired acute hepatic porphyria: a novel type of
37.
Nandi DL, Shemin D.
Delta-aminolevulinic acid dehydratase of Rhodopseudomonas spheroides, II: association to polymers and dissociation to subunits.
J Biol Chem.
1968;243:1231 38. Erskine PT, Senior N, Awan S, et al. X-ray structure of 5-aminolaevulinate dehydratase, a hybrid aldolase. Nat Struct Biol. 1997;4:1025[CrossRef][Medline] [Order article via Infotrieve]. 39. Bonkovsky HL, Healey JF, Lincoln B, Bacon BR, Bishop DF, Elder GH. Hepatic heme synthesis in a new model of experimental hemochromatosis: studies in rats fed finely divided elemental iron. Hepatology. 1987;7:1195[Medline] [Order article via Infotrieve]. 40. Sassa S, Granick S, Kappas A. Effect of lead and genetic factors on heme biosynthesis in the human red cell. Ann N Y Acad Sci. 1975;244:419[CrossRef][Medline] [Order article via Infotrieve].
41.
Fujita H, Koizumi A, Yamamoto M, Kumai M, Sadamoto T, Ikeda M.
Inhibition of
42.
Wetmur JB, Bishop DF, Cantelmo C, Desnick RJ.
Human
43.
Wetmur JG, Kaya AH, Plewinska M.
Molecular characterization of the human
44.
Doss M, Benkmann HG, Goedde HW.
© 2001 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  L. Tang, S. Breinig, L. Stith, A. Mischel, J. Tannir, B. Kokona, R. Fairman, and E. K. Jaffe Single Amino Acid Mutations Alter the Distribution of Human Porphobilinogen Synthase Quaternary Structure Isoforms (Morpheeins) J. Biol. Chem., March 10, 2006; 281(10): 6682 - 6690. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2001 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
-aminolevulinate dehydratase
(ALAD) deficiencies in ALAD porphyria
Top
Abstract
Introduction
-aminolevulinate dehydratase (ALAD) mutants
from patients with ALAD porphyria (ADP) were examined by bacterial
expression of their complementary DNAs and by enzymologic and
immunologic assays. ALADs were expressed as
glutathione-S-transferase (GST) fusion proteins in
Escherichia coli and purified by glutathione-affinity column chromatography. The GST-ALAD fusion proteins were recognized by
anti-ALAD antibodies and were enzymatically active as ALAD. The
enzymatic activities of 3 ALAD mutants, K59N, A274T, and V153M, were
69.9%, 19.3%, and 41.0% of that of the wild-type ALAD, respectively, whereas 6 mutants, G133R, K59N/G133R, F12L, R240W, V275M, and delTC,
showed little activity (< 8%). These variations generally reflect
the phenotype of ALAD in vivo in patients with ADP and indicate that
GST-ALAD fusion protein is indeed useful for predicting of the
phenotype of ALAD mutants. The location of F12L mutation in the
enzyme's molecular structure indicates that its disturbance of the
quaternary contact of the ALAD dimer appears to have a significant
influence on the enzymatic activity. Mouse monoclonal antibodies to
human ALAD were developed that specifically recognized a carboxy
terminal portion of ALAD, or other regions in the enzyme. This study
represents the first complete analysis of 9 mutants of ALAD identified
in ADP and indicates the highly heterogeneous nature of mutations in
this disorder.
(Blood. 2001;97:2972-2978)
)8 or
TIM barrel with the active site located at the C-terminal ends of the